Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma.
Marina Pagnuzzi-BoncompagniVincent PiccoValérie VialVictor Planas-BielsaAshaina VandenbergheThomas DaubonMarie-Alix DerieppeChristopher MontemagnoJérôme DurivaultRenaud GrépinSonia MartialJérôme DoyenJulie GavardGilles PagèsPublished in: Cancers (2021)
Our results suggest that axitinib is a compelling candidate for MB treatment.